NOVOPROTEIN SCIENTIFIC INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.1 CNY | -1.39% |
|
-5.01% | -38.54% |
| Sales 2022 | 265M 36.5M 49.97M | Sales 2023 | 153M 21.14M 28.94M | Capitalization | 3.89B 537M 735M |
|---|---|---|---|---|---|
| Net income 2022 | 90M 12.42M 17M | Net income 2023 | 12M 1.66M 2.27M | EV / Sales 2022 | 13.3 x |
| Net cash position 2022 | 1.82B 251M 343M | Net cash position 2023 | 1.41B 195M 267M | EV / Sales 2023 | 16.2 x |
| P/E ratio 2022 |
47.8
x | P/E ratio 2023 |
308
x | Employees | 579 |
| Yield 2022 |
0.66% | Yield 2023 |
0.9% | Free-Float | 23.4% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.39% | ||
| 1 week | -5.01% | ||
| Current month | -5.07% | ||
| 1 month | -5.17% | ||
| 3 months | -12.18% | ||
| 6 months | -38.15% | ||
| Current year | -38.54% |
1 week
34.06
36.54
1 month
34.0644.44
Current year
30.6756.19
1 year
30.6761.40
3 years
30.67119.46
5 years
30.67119.46
10 years
30.67119.46
| Managers | Title | Age | Since |
|---|---|---|---|
Hua Xing Zhu
CEO | Chief Executive Officer | 52 | 09-09-06 |
Dong Ye Zhang
DFI | Director of Finance/CFO | 51 | 13-06-30 |
De Bin Li
CHM | Chairman | 38 | 12-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fang Ping Zou
BRD | Director/Board Member | 50 | 09-09-30 |
Xia Yun Song
BRD | Director/Board Member | 55 | 21-04-14 |
Hua Xing Zhu
CEO | Chief Executive Officer | 52 | 09-09-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 34.1 | -1.39% | 130 053 |
| 24-06-04 | 34.58 | -2.81% | 324,897 |
| 24-06-03 | 35.58 | -0.95% | 336,554 |
| 24-05-31 | 35.92 | +1.76% | 191,588 |
| 24-05-30 | 35.3 | -1.12% | 218,704 |
End-of-day quote Shanghai S.E., June 04, 2024
More quotes
Novoprotein Scientific Inc is a China-based company mainly engaged in the provision of recombinant protein application solutions. The Company is mainly engaged in the research and development, production and sales of target and factor proteins, recombinant antibodies, enzymes and reagents, and the provision of related technical services. The Company's main products include novel coronavirus diagnostic antibodies, novel coronavirus diagnostic antigens, novel coronavirus pseudoviruses, novel coronavirus non-structural proteins and messenger ribonucleic acid (mRNA) raw materials enzymes and reagents. Its products and services are mainly used in biological medicine, basic research of life science, in vitro diagnosis, mRNA vaccine drugs and other fields. The Company mainly conducts its businesses in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -38.54% | 335M | |
| -0.28% | 90.59B | |
| 0.00% | 38.99B | |
| -8.52% | 34.09B | |
| +64.13% | 26.38B | |
| -17.37% | 15.02B | |
| -5.99% | 13.17B | |
| -10.69% | 11.88B | |
| -47.78% | 10.65B | |
| +8.09% | 9.25B |
- Stock Market
- Equities
- 688137 Stock
